Emergency polytetrafluoroethylene-covered stent implantation to treat right coronary artery perforation during percutaneous coronary intervention by Yorgun, Hikmet et al.
639www.cardiologyjournal.org
CASE REPORT
Cardiology Journal
2012, Vol. 19, No. 6, pp. 639–642
10.5603/CJ.2012.0118
Copyright © 2012 Via Medica
ISSN 1897–5593
Address for correspondence: Ugur Canpolat, MD, Department of Cardiology, Hacettepe University Faculty of Medicine,
Sihhiye, Ankara, P.O. 06100, Turkey, tel: +90 312 305 17 80, fax: +90 312 311 40 58, e-mail: dru_canpolat@yahoo.com
Received: 21.10.2011 Accepted: 22.10.2011
Emergency polytetrafluoroethylene-covered
stent implantation to treat right coronary artery
perforation during percutaneous
coronary intervention
Hikmet Yorgun1, Ugur Canpolat2, Kudret Aytemir2, Ali Oto2
1Elbistan State Hospital, Kahramanmaras, Turkey
2Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Abstract
Coronary artery perforations are life-threatening complications with a poor outcome. Histori-
cally, if the perforation was not controlled using conservative methods such as prolonged
balloon inflation and protamine administration, emergency cardiac surgery has been per-
formed. However, several percutaneous methods including covered stents and embolization
materials have emerged as therapeutic options to manage coronary perforations. We report
a case of right coronary artery perforation after high pressure stent post-dilatation that was
successfully sealed with a polytetrafluoroethylene-covered stent. (Cardiol J 2012; 19, 6: 639–642)
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Introduction
Coronary artery perforation (CAP) is a rare but
life-threatening complication of percutaneous coro-
nary interventions (PCI) [1, 2]. The incidence of
CAP has been reported as 0.2–0.8% among all coro-
nary interventions [3]. Because CAPs may result
in the development of cardiac tamponade and myo-
cardial infarction, emergency coronary artery by-
pass grafting is the standard therapeutic option in
cases of uncontrollable bleeding. However balloon
inflation, covered stent implantation or emboliza-
tion with embolic materials have emerged as im-
portant percutaneous therapeutic methods.
Stents covered with polytetrafluoroethylene
(PTFE) have emerged as an important therapeutic
option in the percutaneous sealing of CAPs. In this
report, we describe a case of emergency life-sav-
ing covered stent implantion in a patient with un-
controllable perforation of the right coronary artery
(RCA) during PCI.
Case report
A 53 year-old man presented with typical chest
pain radiating to his left shoulder and arm. Past
medical history was free of any cardiovascular dise-
ase. Among cardiovascular risk factors, he had
medically controlled dyslipidemia and hypertension.
The patient underwent elective coronary angiogra-
phy which showed critical stenosis in the distal seg-
ment of RCA (Fig. 1A) before crux and non-signi-
ficant lesions in left coronary system. PCI with
stenting was planned for the patient during the same
session. A clopidogrel loading dose of 600 mg with
10,000 IU of intravenous unfractioned heparin were
given prior to procedure. A 6 Fr guiding catheter
was advanced at the level of the root of the aorta
after routine right femoral access. The RCA lesion
was initially crossed with a 0.014 soft guidewire (Asahi
Intecc, Aichi, Japan) and a 3.0 mm × 25 mm bare
metal stent (Multilink Zeta, Abbott Vascular, Ire-
land) was implanted to the lesion with a maximum
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12 atm (nominal pressure: 8 atm; rated burst pres-
sure: 16 atm) pressure. Because of the residual le-
sion, a maximum 18 atm pressure was reached with
the stent balloon. Selective coronary angiography
revealed contrast extravasation to pericardium from
the stented segment of the RCA (Ellis grade III
CAP) (Fig. 1B). Echocardiography confirmed the
presence of pericardial effusion without cardiac tam-
ponade. The hemodynamic status of the patient was
stable. Intravenous protamine was given, with pro-
longed inflation of the balloon at the site of the rup-
ture (Fig. 1C). It was decided to perform a covered
stent implantation due to extravasation of the con-
trast medium after control injections despite con-
servative measures. A 3.0 mm × 19.0 mm JoStent
(Abbott Vascular Devices, Abbott Park, IL, USA)
was deployed to the perforation site successfully
and control injections revealed no extravasation
(Fig. 1D). The patient recovered successfully and
was discharged from hospital three days later with
mild pericardial effusion which had disappeared at
one month control. Dual acetylsalicylic acid and clo-
pidogrel medication was given for six months. At
a  three year control visit, coronary angiography re-
vealed a patent covered stent in the RCA without
restenosis (Fig. 2A, B).
Discussion
Percutaneous coronary intervention has be-
come a leading therapeutic treatment option for
coronary artery disease [4]. With the advance of
new technologies, percutaneous intervention to
complex coronary lesions has increased in recent
years. CAP is a rare but potentially lethal compli-
cation of coronary interventions. In a meta analy-
sis of 16 studies by Shimony et al. [5] involving
197,061 PCIs, the pooled incidence of CAP was
0.43% (95% CI 0.35–0.52%). Traditionally, bypass
surgery has been the preferred treatment for uncon-
trollable perforation; however with the development
of several percutaneous methods including covered
stents or embolic materials, endovascular vessel
sealing has emerged as a first line treatment option.
Several patient-related risk factors have been
found to be associated with the development of
Figure 1. Coronary angiogram showing critical stenosis in the distal segment of right coronary artery (RCA) before
crux (arrow) (A). Angiographic view after stent implantation revealed contrast extravasation to pericardium from the
stented segment of RCA (arrow) (B). Balloon inflation with prolonged duration was performed (C). Because of the
unsuccessful results with conventional methods, polytetrafluoroethylene covered stent implantation was performed
to the perforated segment of the RCA (D).
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CAP, including older age, female gender, hyperten-
sion, history of heart failure, lower creatinine clear-
ance and prior use of antithrombotic agents [6–8].
Also important in the development of CAP are se-
veral angiographic factors including coronary artery
calcification, lesion tortuosity, and type C lesions
and lesion related factors including use of hydro-
philic guidewires, atherectomy devices, intracoro-
nary ultrasound and stent post-dilatation with high
pressure. In our patient, hypertension was the only
patient-related risk factor for the development of
CAP. However, the coronary lesion in the distal
segment of the RCA was not a complex lesion. In
our patient, CAP had developed after high pressure
stent post-dilatation,  which is a risk factor for CAP.
Initially, we inflated an angioplasty balloon at the
level of the perforation to seal the leak. Despite
balloon inflation and intravenous protamine, con-
trast medium leaked into the pericardial cavity in
subsequent injections. The hemodynamic status of
the patient was stable and so we did not perform
pericardiocentesis. Given the unsuccessful results
with balloon inflations, we decided to perform PTFE
covered stent implantation to the lesion as an al-
ternative to surgery, and this sealed the perfora-
tion successfully.
Because of the rarity of CAPs, data was ob-
tained from case reports or small case series. The
management of CAPs is mainly based on the expe-
rience of high volume centers using different meth-
ods. PTFE is an inert and biocompatible polymer
composed of carbon chains saturated with fluorine.
The JoStent GraftmasterVR (Abbott Vascular, Red-
wood City, CA, USA) is a balloon-expandable de-
vice with a single layer of PTFE sandwiched be-
tween two coaxial 316-L stainless steel, slotted-
tube, balloon-expandable stents [9]. Several case
reports have been published about covered stent
treatment of coronary perforation [10–13]. In
a retrospective study with PTFE covered stents,
Briguari et al. [14] reported an improvement in in-
hospital need for emergency cardiac surgery, cardi-
ac tamponade and in-hospital major adverse cardiac
events. However, in a previous single center retro-
spective study, Stankovic et al. [15] reported that
covered stents reduced major adverse cardiac events
only in Ellis type 3 perforations, but not type 2 per-
forations.
In our patient, coronary angiography three years
after covered stent implantation showed that the
PTFE covered stent was patent without restenosis.
The main concerns regarding PTFE covered stents
are stent thrombosis and in-stent restenosis. Initial
studies have reported a rate of 33% for stent throm-
bosis at six months and 50% in-stent restenosis used
for coronary perforations [16, 17]. The proposed
mechanism for those complications was delayed en-
dothelization created by the membrane by PTFE.
However, the first generation stents were not en-
tirely covered with PTFE membrane, which was
modified thereafter. Additionally, thienopyridine
usage was for only 2–4 weeks in those studies.  In
our patient, acetylsalicylic acid and clopidogrel medi-
cation was prolonged to six months and no throm-
botic event was observed. Furthermore, the prog-
nosis of our patient was excellent, and control coro-
nary angiography revealed a patent coronary stent
three years after PTFE covered stent implantation.
Figure 2. Coronary angiography at three year follow-up showing a patent covered stent in distal segment of right
coronary artery at left (A) and right (B) oblique views, with no restenosis.
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In conclusion, despite the controversy surround-
ing the optimal management of CAPs, covered stent
is an important therapeutic option. Our case illustrates
that percutaneous seal of a CAP with a PTFE covered
stent is an effective method, with good mid-term fol-
low-up results. Further improvements in the design
of covered stents may improve outcomes and extend
the use of PTFE covered stents for indications other
than sealing perforations.
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